NovaBay Pharmaceuticals Files 8-K

Ticker: NBY · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1389545

Novabay Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyNovabay Pharmaceuticals, INC. (NBY)
Form Type8-K
Filed DateOct 22, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, pharmaceuticals

TL;DR

NovaBay filed an 8-K on Oct 22 for an Oct 16 event - check for updates.

AI Summary

NovaBay Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting an event on October 16, 2025. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The company, incorporated in Delaware, is in the pharmaceutical preparations industry.

Why It Matters

This 8-K filing signals a material event or update from NovaBay Pharmaceuticals, Inc. that investors should be aware of, potentially impacting its stock.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate indication of significant negative news.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by NovaBay Pharmaceuticals, Inc. on October 16, 2025?

The provided text does not detail the specific 'Other Events' beyond listing the item category.

What financial statements or exhibits are included in this 8-K filing?

The filing indicates 'Financial Statements and Exhibits' are included, but the specific contents are not detailed in this excerpt.

When was NovaBay Pharmaceuticals, Inc. incorporated and in which state?

NovaBay Pharmaceuticals, Inc. was incorporated in Delaware.

What is the principal executive office address for NovaBay Pharmaceuticals, Inc.?

The principal executive office is located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.

What is the filing date of this 8-K report?

This 8-K report was filed on October 22, 2025.

Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-22 16:09:13

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 22, 2025 NovaBay Pharmaceuticals, Inc. By: /s/ Tommy Law Name: Tommy Law Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing